C5 and paroxysmal nocturnal hemoglobinuria: Although the anti-C5 antibodies eculizumab and the long-lasting ravulizumab have been established as the standard of care for PNH patients, effectively reducing adverse events and mortality, unmet needs persist in cases of treatment failure [3,4].